Rocket One Inc. RKTO
focused on developing new generation therapies for unmet medical needs. We are focused on developing (i) a topical formulation for treating
side effects from drugs used for the treatment of cancer (HT-001); (ii) a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT);
and (iii) a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). We also have assets being
developed for (i) atopic dermatitis (also known as eczema) (BioLexa); (ii) a treatment for asthma and allergies using inhalational administration
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| R&D | $5.9M | $3.2M | $3.7M | $4.9M | $7.4M | $2.3M | $2.0M | $785.3K | — |
| SG&A | $6.4M | $5.0M | $4.2M | $6.1M | — | — | — | — | — |
| Total operating expenses | $12.4M | $8.2M | $8.0M | $11.1M | $14.1M | $7.3M | $7.7M | $2.5M | — |
| Operating income | -$12.4M | -$8.2M | -$8.0M | -$11.1M | -$14.1M | -$7.3M | -$7.7M | -$2.5M | — |
| Net income | -$12.5M | -$8.2M | -$8.1M | -$11.4M | -$14.3M | -$7.2M | -$7.7M | -$2.5M | — |
| EPS, basic | -0.90 | -1.28 | -2.38 | -9.50 | -16.02 | — | — | — | — |
| EPS, diluted | -0.90 | -1.28 | -2.38 | -9.50 | -16.02 | -0.58 | -0.84 | -0.50 | — |
| Shares, diluted (wtd. avg.) | $13.8M | $6.4M | $3.4M | $1.2M | $893.2K | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $6.2M | $7.0M | $9.3M | $6.4M | $8.5M | $2.6M | $1.9M | $282.6K | $1.2M |
| Short-term investments | — | — | — | $209.3K | — | — | — | — | — |
| Total current assets | $6.9M | $7.6M | $12.8M | $7.7M | $10.6M | $4.8M | $2.6M | $501.6K | $1.2M |
| Property, plant and equipment | — | — | — | — | — | — | $1.0K | $2.3K | $3.5K |
| Total assets | $7.6M | $7.7M | $12.8M | $7.7M | $11.0M | $5.2M | $2.8M | $503.9K | $1.2M |
| Accounts payable | $823.7K | $412.1K | $35.6K | $695.0K | $361.0K | $129.5K | $403.9K | $142.3K | $47.9K |
| Total current liabilities | $1.5M | $831.2K | $678.7K | $1.4M | $867.8K | $312.1K | $440.1K | $349.0K | $49.5K |
| Total liabilities | $1.5M | $833.9K | $705.0K | $1.6M | $1.1M | $597.1K | $440.1K | $349.0K | $49.5K |
| Retained earnings | -$72.9M | -$60.4M | -$48.2M | -$44.1M | $983.5K | -$19.4M | -$12.2M | -$4.5M | -$2.0M |
| Total equity | $6.2M | $6.9M | $9.5M | $6.1M | $9.9M | $4.6M | $2.4M | $155.0K | $1.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.8M | -$7.0M | -$8.4M | -$9.3M | -$12.1M | -$6.1M | -$4.9M | -$2.1M | — |
| Depreciation and amortisation | — | — | — | — | — | $1.0K | $1.2K | $1.2K | — |
| Stock-based compensation | $1.2M | $804.3K | $216.4K | $620.8K | $1.3M | $737.7K | $2.5M | $143.1K | — |
| Investing cash flow | -$300.0K | — | — | $1.2M | -$165.4K | -$1.8M | -$895.0K | — | — |
| Financing cash flow | $9.3M | $4.7M | $11.3M | $6.0M | $18.2M | $8.7M | $7.5M | $1.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-035625.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |